Who is sponsoring NCT00916760?

NCT00916760 is sponsored by Laboratorios Leti, S.L..

What condition does NCT00916760 study?

NCT00916760 studies Allergic Rhinoconjunctivitis.

What drugs are being tested in NCT00916760?

Interventions: Depigoid Parietaria judaica 1000DPP/ml, Placebo.

What is the status of NCT00916760?

NCT00916760 is currently COMPLETED.

Last reviewed 2013-11-08 · How we verify

Clinical, Multi-centre, Randomised, Double-blind Placebo-controlled Subcutaneous Immunotherapy Trial With Depigmented, Polymerized Extract of Parietaria Judaica Pollen on Patients With Hypersensitivity to This Pollen

NCT00916760 Phase 3 COMPLETED

The objective of this trial is to assess the clinical efficacy of the modified extract (depigmented and polymerized with glutaraldehyde) of the subcutaneous injection of Parietaria Judaica pollen in the treatment of patients affected by allergic rhinitis/rhinoconjunctivitis ( with or without episodic asthma) induced by hypersensitivity to grass pollen, evaluating the score regarding symptoms and consumption of the medication.

Details

Lead sponsor	Laboratorios Leti, S.L.
Phase	Phase 3
Status	COMPLETED
Enrolment	153
Start date	2008-02
Completion	2013-02

Conditions

Allergic Rhinoconjunctivitis

Interventions

Depigoid Parietaria judaica 1000DPP/ml
Placebo

Primary outcomes

Symptoms score — 2 years

Countries

Spain